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BACKGROUND
Up-regulation of hepatic delta-aminolevulinic acid synthase 1 (ALAS1), with resul-
tant accumulation of delta-aminolevulinic acid (ALA) and porphobilinogen, is cen-
tral to the pathogenesis of acute attacks and chronic symptoms in acute hepatic 
porphyria. Givosiran, an RNA interference therapy, inhibits ALAS1 expression.
METHODS
In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 
symptomatic patients with acute hepatic porphyria to receive either subcutaneous 
givosiran (2.5 mg per kilogram of body weight) or placebo monthly for 6 months. 
The primary end point was the annualized rate of composite porphyria attacks 
among patients with acute intermittent porphyria, the most common subtype of 
acute hepatic porphyria. (Composite porphyria attacks resulted in hospitalization, 
an urgent health care visit, or intravenous administration of hemin at home.) Key 
secondary end points were levels of ALA and porphobilinogen and the annualized 
attack rate among patients with acute hepatic porphyria, along with hemin use 
and daily worst pain scores in patients with acute intermittent porphyria.
RESULTS
A total of 94 patients underwent randomization (48 in the givosiran group and 46 
in the placebo group). Among the 89 patients with acute intermittent porphyria, the 
mean annualized attack rate was 3.2 in the givosiran group and 12.5 in the placebo 
group, representing a 74% lower rate in the givosiran group (P<0.001); the results 
were similar among the 94 patients with acute hepatic porphyria. Among the pa-
tients with acute intermittent porphyria, givosiran led to lower levels of urinary ALA 
and porphobilinogen, fewer days of hemin use, and better daily scores for pain than 
placebo. Key adverse events that were observed more frequently in the givosiran 
group were elevations in serum aminotransferase levels, changes in serum creati-
nine levels and the estimated glomerular filtration rate, and injection-site reactions.
CONCLUSIONS
Among patients with acute intermittent porphyria, those who received givosiran 
had a significantly lower rate of porphyria attacks and better results for multiple 
other disease manifestations than those who received placebo. The increased ef-
ficacy was accompanied by a higher frequency of hepatic and renal adverse events. 
(Funded by Alnylam Pharmaceuticals; ENVISION ClinicalTrials.gov number, 
NCT03338816.)
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Acute hepatic porphyria is a family of rare genetic disorders that is caused by defects in heme biosynthesis enzymes.1,2 
Acute intermittent porphyria is the most com-
mon subtype of this disorder and accounts for 
approximately 80% of all symptomatic cases.3-5 
Other, rarer types of acute hepatic porphyria in-
clude hereditary coproporphyria, variegate por-
phyria, and delta-aminolevulinic acid (ALA) dehy-
dratase–deficiency porphyria.2,6,7 Mutations in the 
gene that causes acute intermittent porphyria 
are relatively common (approximately 1 in 1600 
white persons); however, disease penetrance (de-
velopment of symptoms) among mutation car-
riers is approximately 1% in the general popu-
lation and up to 50% in families with a history 
of the disorder.8,9
In patients with acute hepatic porphyria, in-
duction of hepatic ALA synthase 1 (ALAS1) re-
sults in the accumulation of neurotoxic heme 
intermediates, including ALA and porphobilino-
gen (PBG).1,10-12 The accumulation of ALA and 
possibly PBG causes injury to the nervous sys-
tem and other organs, resulting in potentially 
life-threatening acute attacks and chronic dis-
ease manifestations.1,10-12 This disease has been 
associated with long-term coexisting illnesses, 
including chronic kidney disease, hypertension, 
chronic neuropathy, and liver disease (manifested 
as elevated aminotransferase levels, fibrosis, cir-
rhosis, and hepatocellular carcinoma); these 
complications have been attributed to long-term 
elevated levels of ALA and PBG.3,6,13-19 In addi-
tion, patients may have iron overload from re-
peated hemin treatment.20
Attacks that occur in acute hepatic porphyria 
are more commonly seen in females and are 
characterized by severe, diffuse abdominal pain, 
along with muscle weakness, autonomic neurop-
athy (e.g., hypertension, tachycardia, nausea, 
vomiting, and constipation), and changes in 
mental status.3,15,21 Attacks typically warrant ur-
gent medical attention and sometimes prolonged 
hospitalization and rehabilitation.1,15,21 Current 
options for managing attacks include the re-
moval of triggering factors and treatment with 
intravenous opioids, glucose, and hemin.12,21 Most 
symptomatic patients have only a few attacks in 
their lifetime, but up to 8% have recurrent at-
tacks (defined in some cases as four or more 
attacks per year).18 Treatment options for prevent-
ing attacks are limited and include hormone-
suppression therapy, off-label prophylactic hemin, 
and, in rare cases, liver transplantation.7,21,22
Givosiran is a subcutaneously administered 
RNA interference therapeutic targeting hepatic 
ALAS1 messenger RNA (mRNA), thereby pre-
venting the accumulation of ALA and PBG (Fig. 
S1 in the Supplementary Appendix, available 
with the full text of this article at NEJM.org).23 
Givosiran is conjugated to a trivalent N-acetyl-
galactosamine ligand, which binds specifically 
to the asialoglycoprotein receptor, enabling tar-
geted delivery to hepatocytes.24,25
In a phase 1–2 trial, givosiran treatment led 
to rapid and sustained lowering of hepatic levels 
of ALAS1 mRNA and urinary levels of ALA and 
PBG, along with a lower porphyria attack rate 
than placebo, in patients with acute intermittent 
porphyria who were having ongoing attacks.26,27 
Here, we report the efficacy and safety results 
from ENVISION, a multicenter, randomized, 
double-blind, placebo-controlled, phase 3 trial 




The trial was designed by the sponsor, Alnylam 
Pharmaceuticals, in collaboration with the aca-
demic authors. The protocol was approved by a 
central or local institutional review board or 
ethics committee at each trial center. The trial 
was conducted in accordance with Good Clinical 
Practice guidelines of the International Confer-
ence on Harmonisation and the provisions of 
the Declaration of Helsinki. All the patients 
provided written informed consent.
An independent data and safety monitoring 
committee reviewed all pertinent safety data. 
Data were collected by trial investigators and 
staff members and analyzed by the sponsor. 
Medical writers who were employed by the spon-
sor prepared the first draft of the manuscript, 
with editorial assistance provided by Adelphi 
Communications under contract with Alnylam 
Pharmaceuticals. All the authors interpreted the 
data, collaborated in the preparation of the 
manuscript and the decision to submit it for 
publication, and vouch for the accuracy and 
completeness of the data and for the fidelity of 
A Quick Take 
is available at 
NEJM.org
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the trial to the protocol, which is available at 
NEJM.org. All the authors, their institutions, 
and the sponsor were required to maintain data 
confidentiality during the trial.
Patients
Key eligibility criteria included an age of at least 
12 years, a diagnosis of acute hepatic porphyria, 
an elevated level of urinary ALA or PBG (≥4 times 
the upper limit of the normal range [ULN]), and 
either a confirmed pathogenic mutation associ-
ated with acute hepatic porphyria or biochemical 
and clinical criteria consistent with a diagnosis 
of acute hepatic porphyria if such a mutation 
was not identified on genetic testing. (The deter-
mination of the ULN for ALA [1.5 mmol per 
mole of creatinine] and for PBG [0.14 mmol per 
mole of creatinine] was based on samples ob-
tained from 150 healthy persons.15) Patients 
were required to have documentation of at least 
two composite porphyria attacks (i.e., resulting 
in hospitalization, urgent health care, or intrave-
nous administration of hemin at home) within 
6 months before baseline. Patients were also 
required to discontinue or not initiate prophylac-
tic hemin during the trial. Details regarding the 
eligibility requirements are provided in the pro-
tocol and the Supplementary Appendix.
Trial Design and Regimen
Patients were enrolled at 36 sites in 18 countries 
and randomly assigned in a 1:1 ratio to receive 
monthly givosiran (at a dose of 2.5 mg per kilo-
gram of body weight) or placebo26 for 6 months. 
Randomization was stratified according to the 
subtype of acute hepatic porphyria (acute inter-
mittent porphyria with an identified mutation 
vs. any another subtype [hereditary copropor-
phyria, variegate porphyria, ALA dehydratase–
deficiency porphyria with an identified mutation, 
or acute hepatic porphyria without an identified 
mutation]), previous use or nonuse of hemin 
prophylaxis, and a high or low annualized attack 
rate in the previous 12 months (<7 attacks [low] 
vs. ≥7 attacks [high] among patients who were 
receiving hemin prophylaxis at baseline and <12 
attacks [low] vs. ≥12 attacks [high] among those 
who were not receiving hemin prophylaxis). In-
vestigators treated attacks according to the local 
standard of care, which could include intrave-
nous administration of hemin.
Outcome Measures and Safety Assessments
The primary end point was the annualized rate 
of composite porphyria attacks (annualized at-
tack rate) among patients with acute intermit-
tent porphyria during the 6-month intervention 
period. Secondary end points were urinary ALA 
levels (at 3 and 6 months); urinary PBG levels (at 
6 months) in patients with acute intermittent 
porphyria; the annualized number of days of 
hemin use in patients with acute intermittent 
porphyria; the annualized attack rate among all 
patients with acute hepatic porphyria; daily worst 
scores for pain, fatigue, and nausea in patients 
with acute intermittent porphyria; and the change 
from baseline in the score on the Physical Com-
ponent Summary of the 12-Item Short-Form 
Health Survey, version 2 (SF-12), in patients with 
acute intermittent porphyria.28 Daily worst scores 
for pain, fatigue, and nausea were measured on 
a numerical rating scale ranging from 0 to 10, 
with higher scores indicating more severe symp-
toms. Scores on the Physical Component Sum-
mary of the SF-12 range from 0 (worst function-
ing) to 100 (best functioning), with 2 to 5 points 
representing a clinically meaningful difference, 
according to published data for other chronic 
diseases.29,30 Key exploratory end points were the 
use of analgesics as recorded at baseline and 
daily during the intervention period, findings on 
the Patient Global Impression of Change31 regard-
ing the change in overall status since the start of 
the trial, and results on the Porphyria Patient 
Experience Questionnaire regarding the change 
in the perceived treatment experience and in the 
ability to function and perform activities of daily 
living at 6 months. Safety assessments included 
monitoring of adverse events and laboratory as-
sessments. (Details regarding the end points and 
safety assessments are provided in the Supple-
mentary Appendix.)
Statistical Analysis
We estimated that the enrollment of 74 patients 
would provide a power of at least 90% to detect 
a relative lowering of 45% in the annualized at-
tack rate in the givosiran group at a two-sided 
5% significance level, assuming a mean (±SD) 
annualized attack rate of 8±5 in the placebo 
group. The analysis population was the full 
analysis set, including all the patients who had 
undergone randomization and received at least 
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one dose of givosiran or placebo. The primary 
end point and most secondary efficacy end 
points were assessed in patients with acute in-
termittent porphyria with an identified mutation 
to allow for a more homogeneous population for 
an assessment of efficacy.5
The primary analyses of the annualized at-
tack rate and number of days of hemin use were 
based on a negative binomial regression model 
adjusted according to the use of hemin prophy-
laxis and the historical annualized attack rate. 
The analyses of longitudinal secondary efficacy 
end points were based on a mixed model for 
repeated measures. For the end points capturing 
daily worst scores for pain, fatigue, and nausea, 
we calculated the area under the curve of change 
during the 6-month intervention period on the 
basis of the change from baseline in weekly 
mean scores. When the normality assumption 
was violated, a nonparametric Wilcoxon signed-
rank test was conducted to reanalyze the data. 
Secondary end points were analyzed in a pre-
specified hierarchical order to control for the 
overall type I error.32 The handling of missing 
data is described in the statistical analysis plan, 
available in the protocol.
R esult s
Trial Population
From November 16, 2017, through June 27, 2018, 
a total of 94 patients with 64 different genotypes 
were enrolled; during randomization, 48 patients 
were assigned to receive givosiran and 46 to re-
ceive placebo (Fig. S2). All the patients com-
pleted the 6-month visit. The baseline character-
istics of the patients were generally balanced in 
the two groups (Table 1). The mean (±SD) age was 
38.8±11.4 years; 89% of the patients were female.
Of the 94 patients, 89 had acute intermittent 
porphyria. Among the other subtypes of acute 
hepatic porphyria, 1 patient had hereditary copro-
porphyria, 2 had variegate porphyria, and 2 had 
acute hepatic porphyria without an identified 
mutation; both the patients with the last subtype 
were subsequently assessed by the investigator 
as having acute intermittent porphyria on the 
basis of biochemical analysis (Table S1).
The median historical annualized attack rate 
among all the patients was 8 (interquartile 
range, 4 to 16). Baseline levels of ALA and PBG 
were similar in the two randomized groups and 
were markedly elevated above the ULN (see the 
Supplementary Appendix).15 According to the pa-
tients’ medical histories, their coexisting illnesses 
included increased aminotransferase levels (in 
37%), iron overload (in 33%), liver disease (in 
28%), hypertension (in 27%), and renal impair-
ment (in 25%). At baseline, 34% of the patients 
had an estimated glomerular filtration rate 
(eGFR) of less than 60 ml per minute per 1.73 
m2 of body-surface area.
Efficacy
Primary End Point
In patients with acute intermittent porphyria, the 
mean annualized rate of composite porphyria 
attacks over 6 months was 3.2 (95% confidence 
interval [CI], 2.3 to 4.6) in the givosiran group 
and 12.5 (95% CI, 9.4 to 16.8) in the placebo 
group, representing a 74% lower rate in the 
givosiran group (P<0.001) (Fig. 1A). For each of 
the three components of the composite attacks, 
there was a greater reduction in the givosiran 
group than in the placebo group. The median 
annualized attack rate was 1.0 (interquartile 
range, 0.0 to 6.2) in the givosiran group and 10.7 
(interquartile range, 2.2 to 26.1) in the placebo 
group, a relative difference of 90% (Fig. 1B). 
This decrease was evident within the first month 
and was sustained throughout the intervention 
period (Fig. S3). Fifty percent of the patients in 
the givosiran group had no porphyria attacks 
during the intervention period, as compared 
with 17% of those in the placebo group (Fig. S4). 
A prespecified subgroup analysis showed a con-
sistent effect of givosiran on the annualized at-
tack rate across all nine demographic and clini-
cal subgroups (Fig. S5).
Secondary End Points
The key secondary end points are shown in Ta-
ble 2. Among the patients with acute intermit-
tent porphyria, levels of urinary ALA (at 3 and 
6 months) and PBG (at 6 months) were signifi-
cantly lower in the givosiran group than in the 
placebo group (P<0.001). Reductions were sus-
tained throughout the intervention period (Fig. 1C 
and 1D); in the givosiran group, the median 
percent reduction from baseline at 6 months was 
86% for urinary ALA levels and 91% for PBG 
levels.
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Table 1. Demographic and Clinical Characteristics of the Patients at Baseline.*













Age — yr 37.4±10.5 40.1±12.1 38.8±11.4 37.3±10.5 40.7±12.0 39.0±11.4
Female sex — no. (%) 41 (89) 43 (90) 84 (89) 39 (91) 41 (89) 80 (90)
Body-mass index† 25.5±6.4 24.3±5.2 24.9±5.8 25.7±6.3 24.3±5.2 24.9±5.8
Race — no. (%)‡
White 34 (74) 39 (81) 73 (78) 33 (77) 37 (80) 70 (79)
Black 1 (2) 0 1 (1) 0 0 0
Asian 7 (15) 8 (17) 15 (16) 6 (14) 8 (17) 14 (16)
Other 4 (9) 1 (2) 5 (5) 4 (9) 1 (2) 5 (6)
Acute intermittent porphyria with iden-
tified mutation — no. (%)
43 (93) 46 (96) 89 (95) 43 (100) 46 (100) 89 (100)
Nonacute intermittent porphyria§
All subtypes 3 (7) 2 (4) 5 (5) NA NA NA
Hereditary coproporphyria 0 1 (2) 1 (1)
Variegate porphyria 1 (2) 1 (2) 2 (2)
Acute hepatic porphyria without iden-
tified mutation
2 (4) 0 2 (2)¶
No. of yr since diagnosis 8.3±8.5 11.1±11.2 9.7±10.0 8.4±8.7 11.5±11.3 10.0±10.2
Previous hemin prophylaxis — no. (%)
Yes 18 (39) 20 (42) 38 (40) 17 (40) 20 (43) 37 (42)
No 28 (61) 28 (58) 56 (60) 26 (60) 26 (57) 52 (58)
Historical annualized attack rate‖
High — no. (%) 21 (46) 24 (50) 45 (48) 20 (47) 23 (50) 43 (48)
Low — no. (%) 25 (54) 24 (50) 49 (52) 23 (53) 23 (50) 46 (52)
Median rate (IQR) 7 (4–14) 8 (4–18) 8 (4–16) 8 (4–14) 8 (4–18) 8 (4–16)
Previous chronic symptoms — no. (%)**
Yes 26 (57) 23 (48) 49 (52) 24 (56) 22 (48) 46 (52)
No 20 (43) 25 (52) 45 (48) 19 (44) 24 (52) 43 (48)
Previous long-term opioid use — no. 
(%)††
Yes 13 (28) 14 (29) 27 (29) 12 (28) 14 (30) 26 (29)
No 33 (72) 34 (71) 67 (71) 31 (72) 32 (70) 63 (71)
*  Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. IQR denotes interquartile range, and NA not ap-
plicable.
†  The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡  Race was reported by the investigator after discussion with the patient.
§  Porphyria subtypes other than acute intermittent porphyria include hereditary coproporphyria, variegate porphyria, delta-aminolevulinic 
acid (ALA) dehydratase–deficiency porphyria with an identified mutation, and acute hepatic porphyria without an identified mutation. No 
patients with ALA dehydratase–deficiency porphyria were enrolled in this trial.
¶  The two patients with acute hepatic porphyria without an identified mutation were considered by the trial investigator to have acute inter-
mittent porphyria on the basis of biochemical analysis.
‖  The historical annualized attack rate was calculated as the number of attacks resulting in a composite of hospitalization, a visit to a health 
care facility, or hemin use at home during the 6 months before randomization. For patients who were receiving hemin prophylaxis before 
the initiation of the trial, the attack rate was considered to be high if the historical annualized attack rate was 7 or more and low if the at-
tack rate was less than 7 (attack rate of ≥12 and <12, respectively, for patients who were not receiving previous hemin prophylaxis). One 
patient in the placebo group did not meet the inclusion criterion of a history of at least 2 composite porphyria attacks, since the patient 
had 2 attacks that were treated at home without intravenous hemin, which was identified as a protocol deviation.
**  Symptoms were considered to be chronic if patients had symptoms of porphyria daily or on most days when they were not having an at-
tack, as reported by the investigator. Information was reported on a screening questionnaire administered by trial staff members.
††  Opioid use was defined as long-term if patients reported taking an opioid for porphyria daily or most days when they were not having an 
attack, as reported on the screening questionnaire.
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In patients with acute intermittent porphyria, 
the mean annualized number of days of hemin 
use was significantly lower in the givosiran 
group than in the placebo group at 6 months 
(6.8 days vs. 29.7 days, representing a 77% lower 
number in the givosiran group) (P<0.001). Over-
Figure 1. Annualized Attack Rate (AAR) and Urinary Levels of Neurotoxic Heme Intermediates in Patients with Acute 
Intermittent Porphyria.
Panel A shows the mean annualized rate of composite porphyria attacks (the primary end point) among the 89 pa-
tients with acute intermittent porphyria who received either givosiran or placebo. A composite porphyria attack was 
defined as an attack that resulted in hospitalization, an urgent health care visit, or intravenous administration of 
 hemin at home. IV denotes intravenous. Panel B shows the median annualized attack rate, which was calculated 
from the individual patients’ annualized attack rates. Also shown are the median levels of urinary delta-aminolevu-
linic acid (ALA) (Panel C) and porphobilinogen (PBG) (Panel D) in patients with acute intermittent porphyria. In 
Panels C and D, the I bars denote the interquartile range.
C Urinary ALA Levels 
D Urinary PBG Levels
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(N = 46) Difference† P Value
Urinary ALA — mmol/mole of creatinine
Mean (±SD) level at baseline 17.5±10.9 20.0±16.8
Month 3
Least-squares mean (±SE) 20.0±1.5 1.8±1.4 –18.2±2.0 <0.001
Median (IQR) 15.7 (7.5 to 28.9) 0.8 (0.5 to 1.7) –14.6 (–18.0 to 9.6)‡ <0.001
Month 6
Least-squares mean (±SE) 23.2±2.5 4.0±2.4 –19.1±3.5 <0.001
Median (IQR) 16.2 (8.0 to 23.0) 1.3 (0.9 to 4.6) –12.8 (–16.1 to –7.8)‡ <0.001
Urinary porphobilinogen — mmol/mole of creatinine
Mean (±SD) at baseline 46.8±24.3 50.4± 34.3
Least-squares mean (±SE) at 6 mo 49.1±5.0 12.9±4.6 –36.2±6.8 <0.001
Median (IQR) at 6 mo 35.1 (25.6 to 50.0) 4.4 (1.6 to 15.3) –27.5 (–34.0 to –21.0)‡ <0.001
Annualized no. of days of hemin use
Mean (95% CI) 29.7 (18.4 to 47.9) 6.8 (4.2 to 10.9) 0.23 (0.11 to 0.45)§ <0.001
Median (IQR)¶ 27.6 (2.1 to 47.6) 0.0 (0.0 to 10.8)
Annualized attack rate in patients with acute hepatic porphyria
Mean (95% CI) 12.3 (9.2 to 16.3) 3.4 (2.4 to 4.7) 0.27 (0.17 to 0.43)§ <0.001
Median (IQR)¶ 10.7 (2.2 to 25.9) 1.0 (0.0 to 6.4)
Daily worst score for pain‖
Median of change in AUC from baseline (IQR) 5.3 (–23.0 to 11.1) –11.5 (–29.2 to 
3.0)
–10.1 (–22.8 to 0.9)‡ 0.046
Median of average change from baseline (IQR) 0.2 (–1.0 to 0.5) –0.5 (–1.3 to 0.1) –0.4 (–1.0 to 0.1)‡ 0.049
Daily worst score for fatigue‖
Least-squares mean (±SE) of change in AUC from baseline –4.2±4.7 –11.1±4.5 –6.9±6.5 NS
Least-squares mean (±SE) of average change from base-
line
–0.2±0.2 –0.5±0.2 –0.3±0.3 NS
Daily worst score for nausea‖
Least-squares mean (±SE) of change in AUC from baseline –4.0±3.5 1.5±3.3 5.5±4.8 NT
Least-squares mean (±SE) of average change from base-
line
–0.2±0.2 0.1±0.1 0.2±0.2 NT
SF-12**
Mean (±SD) at baseline 38.4±9.4 39.4±9.6 NT
Least-squares mean (±SE) of change from baseline at 6 
mo
1.4±1.2 5.4±1.2 3.9±1.7 NT
*  All secondary end points are reported in patients with acute intermittent porphyria for time points during the 6-month intervention period 
unless otherwise stated. ALA denotes delta-aminolevulinic acid, AUC area under curve, CI confidence interval, and NS not significant. 
Statistical significance was not tested (NT) if the end point did not meet the conditions of the prespecified hierarchical order.
†  Differences are for the givosiran group, as compared with the placebo group.
‡  Because of a significant deviation from normal distribution, the planned methods of a mixed model for repeated measures or analysis 
of covariance were not valid. A nonparametric stratified Wilcoxon signed-rank test was therefore conducted. The median of the between-
group difference was estimated with the use of the Hodges–Lehmann method.
§  This value is a rate ratio (95% CI) for the comparison between givosiran and placebo.
¶  The between-group difference in the median values in this category was not calculated with the use of statistical models.
‖  Scores for pain, fatigue, and nausea were measured on a numerical rating scale ranging from 0 to 10, with higher scores indicating more 
severe symptoms.
**  Scores on the Physical Component Summary of the 12-Item Short-Form Health Survey, version 2 (SF-12), range from 0 (worst function-
ing) to 100 (best functioning), with published literature in other chronic diseases suggesting that a change of 2 to 5 points represents a 
clinically meaningful difference.
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all, 54% of the patients in the givosiran group 
had no days of hemin use, as compared with 
23% of those in the placebo group. Among all 
the patients with acute hepatic porphyria, the 
mean annualized attack rate was significantly 
lower in the givosiran group than in the placebo 
group at 6 months, representing a 73% lower 
rate in the givosiran group (P<0.001) (Table S2). 
Among the patients with acute intermittent por-
phyria, the worst daily pain score was signifi-
cantly lower in the givosiran group than in the 
placebo group (P = 0.046 by post hoc Wilcoxon 
signed-rank test) (Fig. S6). There were no sig-
nificant between-group differences in the worst 
daily scores for fatigue or nausea.
Among the patients with acute intermittent 
porphyria, the mean (±SE) change from baseline 
in the Physical Component Summary of the SF-12 
was 3.9±1.7 points higher (indicating improve-
ment) in the givosiran group than in the placebo 
group at 6 months. Results across SF-12 do-
mains showed a consistent effect favoring givo-
siran over placebo, with the largest effects re-
garding bodily pain, social functioning, and role 
limitations due to physical problems (Fig. S7).
Exploratory End Points
The percentage of patients with acute intermit-
tent porphyria who used any opioids during the 
trial period was 67% in the givosiran group and 
88% in the placebo group; the median percent-
age of days of opioid use during the intervention 
period was 3.0% (interquartile range, 0.0 to 38.5) 
and 10.8% (interquartile range, 2.4 to 83.3), re-
spectively. On the Patient Global Impression of 
Change at 6 months in patients with acute he-
patic porphyria, the percentage that rated overall 
health status as either “much improved” or “very 
much improved” was 59% in the givosiran group 
and 18% in the placebo group. On the Porphyria 
Patient Experience Questionnaire in patients with 
acute hepatic porphyria, the percentage who had 
improvements from baseline in their ability to 
function and perform activities of daily living 
and in treatment satisfaction was larger in the 
givosiran group than in the placebo group (Fig. 
S8A and S8B).
Safety
Adverse events are listed in Table 3. Overall, 
adverse events were reported by 90% of the pa-
tients in the givosiran group and 80% of those 
in the placebo group. Adverse events that were 
reported more frequently in the givosiran group 
than in the placebo group were injection-site reac-
tions, nausea, chronic kidney disease, decreased 
eGFR, rash, increased alanine aminotransferase 
(ALT) levels, and fatigue.
The percentage of serious adverse events was 
higher in the givosiran group than in the placebo 
group (21% vs. 9%) (Table S3). The difference 
in serious adverse events was not driven by any 
particular event. Serious adverse events that 
were reported in at least 2 patients were worsen-
ing of chronic kidney disease (in 2 patients in 
the givosiran group) and events consistent with 
central venous catheter infection (in 1 patient in 
the givosiran group and 2 patients in the place-
bo group). One patient in the givosiran group 
discontinued treatment because of abnormal 
results on liver-function testing; this occurrence 
was reported as a serious adverse event. There 
were no deaths.
Hepatic adverse events, as characterized by 
elevations in serum aminotransferase levels, were 
more frequent in the givosiran group than in the 
placebo group (Tables S4 and S5). An ALT level 
of more than 3 times the ULN was reported in 
7 patients (15%) in the givosiran group and in 
1 (2%) in the placebo group. These increases oc-
curred primarily 3 to 5 months after the initia-
tion of givosiran and placebo; all the events were 
reported as hepatic adverse events except for one 
in a patient in the givosiran group who had a 
history of nonalcoholic steatohepatitis, in whom 
the investigator considered that the elevated ALT 
level was consistent with previous values. In the 
givosiran group, for 1 patient who had an ALT 
elevation of 9.9 times the ULN, the abnormal 
results on liver-function testing were reported as 
a serious adverse event; in this case, the patient 
permanently discontinued treatment with givo-
siran, in accordance with the stopping rules pre-
specified in the protocol. The elevation resolved 
with normal ALT values at 6 months. No other 
adverse events led to treatment discontinuation 
or withdrawal from the trial. In 1 patient with 
an ALT elevation of 5.4 times the ULN, the ad-
ministration of givosiran was temporarily inter-
rupted, in accordance with the protocol-speci-
fied dosing rule, and was resumed at a lower 
dose (1.25 mg per kilogram) after resolution, 
without recurrence of the ALT elevation. The 
other 5 patients who had an ALT level of more 
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than 3 times the ULN had resolution of the ALT 
elevations with continued dosing (at 2.5 mg per 
kilogram). Elevations of serum aminotransfer-
ase levels were seen at similar frequencies and 
degrees in patients with or without elevated 
aminotransferase levels at baseline.
Renal adverse events were reported in 15% of 
the patients in the givosiran group and in 7% of 






no. of patients (%)
Any adverse event 37 (80) 43 (90)
Any severe adverse event 5 (11) 8 (17)
Any serious adverse event 4 (9) 10 (21)
Any adverse event leading to discontinuation of the trial regimen 0 1 (2)
Death 0 0
Adverse events with higher frequency (≥5 percentage points)  
in the givosiran group
Injection-site reaction† 0 12 (25)
Nausea 5 (11) 13 (27)
Chronic kidney disease 0 5 (10)
Decreased eGFR 0 3 (6)
Rash 0 3 (6)
Increased alanine aminotransferase 1 (2) 4 (8)
Fatigue 2 (4) 5 (10)
Adverse events with higher frequency (≥5 percentage points)  
in the placebo group
Pyrexia 6 (13) 1 (2)
Hypoesthesia 4 (9) 0
Dyspepsia 4 (9) 0
Vomiting 5 (11) 2 (4)
Urinary tract infection 6 (13) 3 (6)
Back pain 4 (9) 1 (2)
Adverse events of interest
Hepatic‡ 1 (2) 6 (13)
Renal§
Any event 3 (7) 7 (15)
Increased serum creatinine or decreased eGFR¶ 2 (4) 7 (15)
*  Serious adverse events were defined as adverse events that resulted in death, were life-threatening, required in-patient 
hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, 
were a congenital anomaly or birth defect, or were important medical events as determined by the investigators. All ad-
verse events (including serious adverse events) were graded for severity. Severe events were adverse events for which 
more than minimal, local, or noninvasive intervention was indicated; had a more severe effect on limiting self-care ac-
tivities of daily living; or had potential for life-threatening consequences or death.
†  Injection-site reactions include all adverse events that are included under the term of high-level injection-site reactions 
in the Medical Dictionary for Regulatory Activities (MedDRA).
‡  Hepatic adverse events included elevated aminotransferase levels, which occurred in each of the 7 patients in the givo-
siran group and were selected according to MedDRA terms for drug-related hepatic disorders.
§  Renal adverse events included all events selected according to MedDRA terms for chronic kidney disease.
¶  This category includes a subgroup of patients who had changes in the serum creatinine level or estimated glomerular 
filtration rate (eGFR) that were reported as an increased blood creatinine level, a decreased eGFR, chronic kidney dis-
ease, or nephropathy.
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those in the placebo group (Table S6); the major-
ity of these events were an increase in the serum 
creatinine level or a reduction in the eGFR. Of 
these events, 5 patients in the givosiran group 
had either the onset or worsening of chronic 
kidney disease (Table S7), and 1 patient in the 
placebo group had worsening nephropathy, all of 
which were associated with an increased creati-
nine level and a decreased eGFR. Two patients 
in the givosiran group who had worsening of 
chronic kidney disease (which was reported as a 
serious adverse event) had renal-biopsy results that 
were consistent with their underlying coexisting 
illnesses (hypertension and porphyria-associated 
nephropathy). No patients discontinued either 
givosiran or placebo because of a renal adverse 
event.
Overall, an analysis of renal measures showed 
that increases in the serum creatinine level (me-
dian increase at 3 months, 0.07 mg per deciliter 
[6.2 μmol per liter]) and corresponding decreas-
es in the eGFR (Fig. S9) were noted early during 
givosiran treatment; both findings were mainly 
reversible over time without any dose modifica-
tions. Stratification of patients according to the 
baseline category of eGFR did not show an in-
creased percentage of renal impairment (as as-
sessed by the eGFR) in any group.
Injection-site reactions occurred in 25% of 
the patients in the givosiran group and were as-
sociated with 7% of 279 givosiran doses. All the 
reactions were mild or moderate in severity, and 
none led to discontinuation. There were no 
clinically significant elevations in amylase or li-
pase levels and no development of antidrug anti-
bodies. (Details regarding all adverse advents are 
provided in the Supplementary Appendix.)
Discussion
Patients who have acute hepatic porphyria with 
ongoing attacks have a severe disease burden 
and limited treatment options. In such patients, 
we found that a givosiran-mediated reduction in 
hepatic ALAS1 mRNA resulted in a sustained 
lowering of heme intermediates ALA and PBG, 
which are thought to cause the manifestations 
of this disorder.1,11,12 To ensure a homogeneous, 
enriched population for an evaluation of the ef-
ficacy of givosiran, we assessed the primary end 
point and most secondary end points in patients 
with genetically confirmed acute intermittent 
porphyria, the most common subtype of acute 
hepatic porphyria.
Among 89 such patients, the annualized rate 
of composite porphyria attacks (the primary end 
point) was 74% lower in the givosiran group 
than in the placebo group; among 94 patients 
with acute hepatic porphyria, the rate was 73% 
lower — differences that were both significant 
and clinically meaningful. Such between-group 
differences were observed within the first month 
of treatment and were sustained throughout the 
intervention period, with 50% of patients having 
no porphyria attacks while they were receiving 
givosiran. A consistent effect on the annualized 
attack rate was observed across all nine pre-
specified subgroups, which showed the extent of 
the treatment effect. Givosiran treatment in pa-
tients with acute intermittent porphyria also led 
to sustained reductions in levels of ALA and 
PBG, with beneficial effects across a broad range 
of acute and chronic disease manifestations. 
These effects were shown by secondary and ex-
ploratory efficacy measures that included hemin 
use, daily worst pain, analgesic use, physical 
functioning, overall health and well-being, ac-
tivities of daily living, and treatment satisfac-
tion, as compared with placebo. More than 50% 
of the patients in the givosiran group did not 
receive any hemin infusions during the trial. 
Such reductions in hemin use may be beneficial, 
since hemin is potentially associated with both 
acute side effects (e.g., headache, fever, and 
phlebitis) and chronic side effects (e.g., iron 
overload, venous obliteration, and complications 
with indwelling central venous catheters).17,20,33
The cardinal symptom of acute hepatic por-
phyria, neuropathic pain, is often refractory to 
treatment and requires complex analgesic regi-
mens.6,34,35 Givosiran-treated patients with acute 
intermittent porphyria had better daily pain 
scores and less analgesic use than those who 
received placebo. Improvements in physical health 
status and in the bodily pain domain of the SF-12 
may suggest that the observed better scores for 
pain were clinically relevant. Although between-
group differences in daily scores for worst fa-
tigue and nausea were not observed during the 
6-month treatment period, the trial was not spe-
cifically enriched for patients with high baseline 
scores for chronic symptoms.
The main safety finding was elevations in 
serum aminotransferase levels, which were re-
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ported primarily during the 3 to 5 months after 
initiation of the trial regimen. Most patients 
with elevations had resolution with continued 
administration of givosiran, which suggests adap-
tation by the liver. Of the patients with ALT 
values of more than three times the ULN, most 
had a medical history of liver disease (e.g., por-
phyria-related liver disease, increased amino-
transferase levels, and iron overload). No pa-
tients with an elevated ALT level had concomitant 
elevations in levels of total bilirubin of more 
than two times the ULN.
Chronic kidney disease is a commonly recog-
nized coexisting illness and long-term complica-
tion of acute hepatic porphyria,13,15 and approxi-
mately one third of patients in the trial had a 
reduced eGFR (<60 ml per minute per 1.73 m2) 
at baseline. There was a greater frequency of renal 
adverse events, as characterized by an increased 
serum creatinine level and associated decreases 
in the eGFR, with givosiran than with placebo. 
The mechanism of these changes is unknown. 
The results of analyses of renal-biopsy samples 
obtained from two patients with chronic kidney 
disease and hypertension were consistent with 
the patients’ underlying coexisting illnesses and 
showed no signs of an adverse drug effect (e.g., 
acute tubular toxicity, immune complexes, and 
glomerulonephritis). Overall, increased levels of 
serum creatinine and decreases in the eGFR oc-
curred early during the 6-month period and were 
mostly transient and reversible. Renal function 
should be monitored during givosiran treatment, 
as clinically indicated.
It has been hypothesized that decreasing 
ALAS1 expression could lead to hepatic heme 
deficiency and affect the activity of heme-depen-
dent enzymes (e.g., cytochrome P450 [CYP]). In 
a drug–drug interaction study involving patients 
with acute intermittent porphyria who were not 
having porphyria attacks, givosiran was associ-
ated with a moderate effect on CYP1A2 and 
CYP2D6, a weak effect on CYP2C19 and CYP3A4, 
and no effect on CYP2C9.36 These results suggest 
that givosiran does not have a strong effect on 
hepatic heme content or heme-dependent en-
zyme activity.
Limitations of this trial include the 6-month 
duration of the intervention period. Data from 
an ongoing phase 1–2 open-label extension study 
of givosiran (median duration, 26 months) have 
shown sustained reductions in the annualized 
attack rate, in levels of ALA and PBG, and in 
hemin use.27 In addition, limited data were ob-
tained in patients with subtypes of acute hepatic 
porphyria other than acute intermittent por-
phyria because of the extreme rarity of such 
patients who have ongoing attacks. Our findings 
suggest that patients with all subtypes of acute 
hepatic porphyria would probably derive similar 
clinical benefits from givosiran, since the sub-
types have common pathophysiological features 
and treatment, along with the reduced levels of 
ALA and PBG seen in the givosiran-treated pa-
tients with hereditary coproporphyria and varie-
gate porphyria. We are currently evaluating the 
long-term efficacy and safety of givosiran during 
the open-label extension period of the ENVISION 
trial involving patients with all subtypes of acute 
hepatic porphyria.
Thus, in the ENVISION phase 3 trial, we 
found that patients with acute intermittent por-
phyria who received givosiran for 6 months had 
a significantly lower annualized rate of por-
phyria attacks and better results regarding mul-
tiple other disease manifestations than those 
who received placebo. The use of givosiran was 
associated with an acceptable safety profile, al-
though patients had a higher frequency of he-
patic and renal adverse events. On the basis of 
these results, givosiran was approved for the 
treatment of acute hepatic porphyria in adults by 
the Food and Drug Administration on November 
20, 2019, and by the European Medicines Agency 
(EMA) on March 3, 2020; the EMA also approved 
the use of givosiran in adolescents older than 12 
years of age.37,38
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